Bosentan in the treatment of pulmonary arterial hypertension with the focus on the mildly symptomatic patient
Christopher J Valerio, John G CoghlanDepartment of Cardiology, Royal Free Hospital, London, UKAbstract: Pulmonary arterial hypertension (PAH) is a progressive disease with poor survival outcomes. Bosentan is an oral endothelin-1 receptor antagonist (ERA) that has been shown in a large randomized pla...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2009-08-01
|
| Series: | Vascular Health and Risk Management |
| Online Access: | http://www.dovepress.com/bosentan-in-the-treatment-of-pulmonary-arterial-hypertension-with-the--a3409 |